rezatapopt + pembrolizumab
Advanced Solid Tumors with p53 Y220C mutation
Key Facts
Indication
Advanced Solid Tumors with p53 Y220C mutation
Phase
Phase 1/2
Status
Active (Combination Arm)
Company
About PMV Pharma
PMV Pharma's mission is to conquer cancer by restoring the function of the most frequently mutated tumor suppressor, p53. The company's key achievement is advancing rezatapopt, a first-in-class p53 Y220C reactivator, into a pivotal Phase 1/2 trial (PYNNACLE) with Fast Track designation and publishing compelling first-in-human data in the New England Journal of Medicine. Its strategy leverages a deep structural biology platform to develop tumor-agnostic therapies targeting specific p53 hotspot mutations, aiming to address a major unmet need in approximately 50% of all cancers.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors with p53 Y220C mutation Drugs
| Drug | Company | Phase |
|---|---|---|
| rezatapopt (PC14586) | PMV Pharma | Phase 1/2 |